Brad Liston, DO
Adult Medicine · Ponca City, OKNPI 1487817375
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 554 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 37.2% of the total.
Across 554 payments — averaging $15.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$1K
- Novo Nordisk$1K
- Boehringer Ingelheim$597
- Merck$421
- Johnson & Johnson$371
- plus $1K from 23 others
What the payments were for
- Food & beverage$8,303100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 154 | $3,097 |
| GSK | 134 | $1,381 |
| Novo Nordisk | 83 | $1,063 |
| Boehringer Ingelheim | 39 | $597 |
| Merck | 26 | $421 |
| Johnson & Johnson | 32 | $371 |
| Pfizer | 14 | $237 |
| Exact Sciences | 11 | $190 |
| Lilly USA, LLC | 12 | $187 |
| Amgen | 10 | $155 |
| Mylan Specialty L.p. | 6 | $100 |
| Amarin Pharma, Inc. | 5 | $69 |
| AbbVie(2 entities) | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Viatris Specialty LLC | 2 | $40 |
| Novartis | 2 | $37 |
| Eisai Inc. | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Dexcom, Inc. | 2 | $30 |
| Bayer | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| UCB, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few adult medicine providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 164 | $173,976 |
| JanuviaSitagliptin Phosphate | 119 | $95,541 |
| JardianceEmpagliflozin | 133 | $93,703 |
| FarxigaDapagliflozin Propanediol | 105 | $86,974 |
| TrulicityDulaglutide | 57 | $54,035 |
| EliquisApixaban | 69 | $53,469 |
| OzempicSemaglutide | 54 | $49,445 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $31,378 |
| XareltoRivaroxaban | 39 | $21,050 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $20,447 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $15,908 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $15,740 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $13,474 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $12,116 |
| InvokanaCanagliflozin | 23 | $11,557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $187 | $228,011221 claims |
| MerckJanuvia, Janumet | $421 | $111,450136 claims |
| Boehringer IngelheimJardiance | $597 | $93,703133 claims |
| AstraZenecaFarxiga, Symbicort | $3,097 | $91,565116 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,381 | $59,233102 claims |
| PfizerEliquis | $237 | $53,46969 claims |
| Novo NordiskOzempic | $1,063 | $49,44554 claims |
| Johnson & JohnsonXarelto, Invokana | $371 | $32,60762 claims |
| AbbVieSynthroid | $53 | $4,88892 claims |
| Sanofi-aventis U.S. LLCLantus | $41 | $2,80913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other adult medicine in Ponca City
- Larhonda SimsOklahoma City$751
- James RitzeBroken Arrow$462
- Bejoy KurianOklahoma City$385
- Thomas CrowWaurika$339
- Larry SumnerTahlequah$249
- William McAfeeOklahoma City$219
- Carol KerrIdabel$205
- Robert FisherOklahoma City$135
- Chad PhillipsTulsa$78
- Keiah WilliamsTulsa$41
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.